Engineered immune cells take on Hard-to-Treat leukemia and lymphoma
NCT ID NCT07162571
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 32 times
Summary
This study tests a new treatment using a patient's own immune cells, modified to target and kill cancer cells. It is for adults with leukemia or lymphoma that has come back or not responded to standard therapy. The goal is to see if the treatment is safe and can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
State Institution Minsk Scientific and Practical Center for Surgery, Transplantology, and Dermatology
Minsk, 220087, Belarus
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.